Florian Hohla

2.4k total citations · 1 hit paper
41 papers, 1.8k citations indexed

About

Florian Hohla is a scholar working on Oncology, Epidemiology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Florian Hohla has authored 41 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 16 papers in Epidemiology and 11 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Florian Hohla's work include Growth Hormone and Insulin-like Growth Factors (11 papers), Neuroendocrine Tumor Research Advances (9 papers) and Cancer-related Molecular Pathways (7 papers). Florian Hohla is often cited by papers focused on Growth Hormone and Insulin-like Growth Factors (11 papers), Neuroendocrine Tumor Research Advances (9 papers) and Cancer-related Molecular Pathways (7 papers). Florian Hohla collaborates with scholars based in Austria, United States and Germany. Florian Hohla's co-authors include Andrew V. Schally, Christian Datz, Elmar Aigner, Stefan Buchholz, Wolfgang Patsch, Bassel F. El‐Rayes, Peter J. Allen, Jason E. Faris, Peter J. Hosein and Andreas Stadlmayr and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Florian Hohla

40 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis

2016 653 citations Florian Hohla et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Florian Hohla Austria	23	1.0k	592	411	349	338	41	1.8k
Tetsuro Ishikawa Japan	25	763 0.7×	283 0.5×	269 0.7×	419 1.2×	420 1.2×	136	2.0k
Klaus Baumann Germany	22	1.0k 1.0×	225 0.4×	421 1.0×	378 1.1×	155 0.5×	84	2.2k
Gui‐Qi Zhu China	26	382 0.4×	597 1.0×	268 0.7×	646 1.9×	117 0.3×	78	2.0k
Sri Harsha Tella United States	23	967 0.9×	205 0.3×	414 1.0×	818 2.3×	435 1.3×	95	2.5k
Antonia Martinetti Italy	32	1.5k 1.5×	837 1.4×	618 1.5×	685 2.0×	274 0.8×	121	2.8k
Jun Liang China	24	402 0.4×	204 0.3×	316 0.8×	550 1.6×	638 1.9×	104	1.8k
Ilaria Ruffilli Italy	27	528 0.5×	248 0.4×	237 0.6×	469 1.3×	1.1k 3.2×	54	2.2k
Lawrence A. Shirley United States	21	577 0.6×	171 0.3×	179 0.4×	525 1.5×	199 0.6×	48	1.5k
Stefan Barlage Germany	19	751 0.7×	242 0.4×	218 0.5×	1.0k 2.9×	308 0.9×	31	2.5k
Luigi Rossi Italy	20	342 0.3×	154 0.3×	332 0.8×	400 1.1×	104 0.3×	58	1.5k

Countries citing papers authored by Florian Hohla

Since Specialization

Citations

This map shows the geographic impact of Florian Hohla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Florian Hohla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Florian Hohla more than expected).

Fields of papers citing papers by Florian Hohla

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Florian Hohla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Florian Hohla. The network helps show where Florian Hohla may publish in the future.

Co-authorship network of co-authors of Florian Hohla

This figure shows the co-authorship network connecting the top 25 collaborators of Florian Hohla. A scholar is included among the top collaborators of Florian Hohla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Florian Hohla. Florian Hohla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schlick, Konstantin, Jutta Auberger, Jan Marco Kern, et al.. (2015). Cytomegalovirus reactivation and its clinical impact in patients with solid tumors. Infectious Agents and Cancer. 10(1). 45–45. 35 indexed citations

Seitz, Stephan, Stefan Buchholz, Andrew V. Schally, et al.. (2014). Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125. BMC Cancer. 14(1). 847–847. 47 indexed citations

Stadlmayr, Andreas, Elmar Aigner, Ursula Huber-Schönauer, et al.. (2014). Relations of vitamin D status, gender and type 2 diabetes in middle-aged Caucasians. Acta Diabetologica. 52(1). 39–46. 32 indexed citations

Hohla, Florian. (2014). Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives. World Journal of Gastroenterology. 20(20). 6102–6102. 40 indexed citations

Seitz, S., Ferenc G. Rick, Andrew V. Schally, et al.. (2013). Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers. Oncology Reports. 30(1). 413–418. 26 indexed citations

Hohla, Florian, Georg Hopfinger, Gabriel Rinnerthaler, et al.. (2013). Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: A single institution retrospective review. International Journal of Oncology. 44(1). 319–326. 36 indexed citations

Bezan, Angelika, et al.. (2013). Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report. BMC Cancer. 13(1). 618–618. 11 indexed citations

Rick, Ferenc G., Stefan Buchholz, Andrew V. Schally, et al.. (2012). Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers. Cell Cycle. 11(13). 2518–2525. 23 indexed citations

Seitz, Stephan, Stefan Buchholz, Andrew V. Schally, et al.. (2012). Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124]. Anti-Cancer Drugs. 24(2). 150–157. 16 indexed citations

10.

Hohla, Florian, et al.. (2012). A 55-year-old woman with locally advanced rectal cancer and a resectable synchronous hepatic metastasis: a case report. memo - Magazine of European Medical Oncology. 5(4). 273–276. 1 indexed citations

11.

Stadlmayr, Andreas, Elmar Aigner, Bernhard Steger, et al.. (2011). Nonalcoholic fatty liver disease: an independent risk factor for colorectal neoplasia. Journal of Internal Medicine. 270(1). 41–49. 106 indexed citations

12.

Hohla, Florian & Andrew V. Schally. (2010). Targeting gastrin releasing peptide receptors: New options for the therapy and diagnosis of cancer. Cell Cycle. 9(9). 1738–1741. 55 indexed citations

13.

Kovács, Magdolna, Andrew V. Schally, Florian Hohla, et al.. (2010). A correlation of endocrine and anticancer effects of some antagonists of GHRH. Peptides. 31(10). 1839–1846. 22 indexed citations

14.

Hohla, Florian, Stefan Buchholz, Andrew V. Schally, et al.. (2010). Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells. Cancer Letters. 294(1). 35–42. 24 indexed citations

15.

Hohla, Florian, Stefan Buchholz, Andrew V. Schally, et al.. (2009). GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells. Cell Cycle. 8(19). 3149–3156. 35 indexed citations

16.

Seitz, Stephan, Andrew V. Schally, Andrea Treszl, et al.. (2009). Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition. Anti-Cancer Drugs. 20(7). 553–558. 20 indexed citations

17.

Aigner, Elmar, Jessica Pfleger, Florian Hohla, et al.. (2009). Iron stores, liver transaminase levels and metabolic risk in healthy teenagers. European Journal of Clinical Investigation. 40(2). 155–163. 24 indexed citations

18.

Köster, Frank, J. Engel, Andrew V. Schally, et al.. (2008). Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition. Breast Cancer Research and Treatment. 116(2). 273–279. 23 indexed citations

19.

Aigner, Elmar, Igor Theurl, Heike Haufe, et al.. (2008). Copper Availability Contributes to Iron Perturbations in Human Nonalcoholic Fatty Liver Disease. Gastroenterology. 135(2). 680–688.e1. 123 indexed citations

20.

Heinrich, Elmar, Andrew V. Schally, Stefan Buchholz, et al.. (2008). Dose‐dependent growth inhibition in vivo of PC‐3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ‐J‐7‐138. The Prostate. 68(16). 1763–1772. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact